合作邀请函 | 沙利文即将发布《2026医美注射类产品白皮书》

In 2026, the market for Chinese medical aesthetics injectables is at a critical stage of structural transformation.

Overall, the industry is shifting from the expansion of a single material to a new cycle of multi-material collaboration, technological innovation, and compliance focus. Various injectable products continue to make progress in material science, bioengineering, and clinical applications, expanding the clinical boundaries of facial rejuvenation and tissue repair.

At the same time, the systematic improvement of regulatory systems is reshaping industry operating rules. Deepened implementation of tax regulations, pharmaceutical and medical device traceability, and special governance measures have significantly raised compliance requirements, establishing a institutional foundation for long-term healthy development. Technologically, the auxiliary value of artificial intelligence in diagnostic and treatment decisions is becoming increasingly evident, and the potential for synthetic biology to innovate raw material supply methods is also being realized. On the consumer side, markets at different levels and differentiated demands are growing simultaneously, providing diverse value opportunities for the industry.

Based on long-term tracking and in-depth research in life sciences and cutting-edge medicine, Frost & Sullivan (hereinafter referred to as "Frost & Sullivan") plans to officially release the '2026 Blue Book on Medical Aesthetics Injectables' in 2026. We invite outstanding enterprises and industry partners in the industry to participate together, promoting the standardization and innovative development of the Chinese medical aesthetics injectables industry.

Research Content

The Blue Book will systematically analyze the development pattern and evolution trend of the Chinese medical aesthetics injectables industry in 2026, focusing on core categories such as hyaluronic acid, collagen, botulinum toxin, regenerative materials,exosomesand emerging materials. It will conduct research from aspects such as material science progress, clinical application expansion, regulatory policy evolution, industry competition landscape, and consumer demand changes, providing a structural understanding of the overall industry situation, aiming to offer professional references to industry participants.

1. Material Science Progress

The Blue Book will deeply analyze key technological breakthroughs of various injectable materials in 2026:Hyaluronic Acidfield,the refined iteration of cross-linking processesand low-modification technology routes continuously enhance product performance;Collagenfield, the recombinant expression system has made substantial progress in expression amount, biological activity, and batch consistency, while animal-derived extraction processes are continuously optimized in terms of immunogenicity control and activity retention;Botulinum Toxinfield, the recombinant preparation path and differential development of new serotypes expand clinical options;Regenerative Materialsfield, large-scale production of raw materials is changing the supply structure;Emerging Materialsin terms of the industrialization feasibility of various new biopolymers under synthetic biology pathways has been verified.

2. Core Application Scenarios

The Blue Book will conduct in-depth interviews with medical aesthetic institutions and end consumers, combining clinical literature and industry data to systematically examine the current application status of injectable products in core scenarios such as facial volume filling and contour shaping, dynamic wrinkle management, tissue regeneration and skin quality improvement, and composite treatment plans. Special attention will be given to the trend of the indication system expanding to more precise areas.

Institutional interviews will focus on decision-making logic for product selection, treatment plan design, joint treatment strategies, complication management experience, and compliance procurement considerations;

Consumer interviews will cover information acquisition paths, product awareness levels, decision-making factors, expected efficacy and actual satisfaction, repeat purchase and recommendation intentions, price sensitivity, and acceptance of emerging materials. The goal is to present the value positioning and optimization space of injectable products in real clinical scenarios and consumer decisions from both supply and demand perspectives.

3. Industry Development Drivers

The Blue Book will focus on analyzing multiple drivers of the industry: the evolution of the age structure and aesthetic concepts of consumer groups creates differentiated demands, the increase in penetration in lower markets brings incremental space, the cross-empowerment of synthetic biology and AI technologies reshapes research and development efficiency and supply methods, the systematic improvement of regulatory frameworks helps the industry enter a standardized development track, and continuous attention from capital to innovative materials and platforms provides motivation for industry integration.

4. Industry Competition Landscape

The Blue Book will comprehensively present the competitive ecosystem of the Chinese medical aesthetics injectables market. With product type as the main line of research, it will coverhyaluronic acid, collagen, botulinum toxin, regenerative materials, emerging materialsfield technical routes, product pipeline layout, clinical registration progress, and commercialization strategies. Through specific cases, the competition logic and development trends in this field will be revealed. The aim is to provide readers with structured insights that combine industry breadth and depth.

5. Regulation and Access Policies

The Blue Book will systematically review the updates to the regulatory framework for Chinese medical aesthetics injectables products, including newly issued registration review guidelines in 2026, requirements for the establishment of pharmaceutical and medical device traceability systems, special governance measures for key categories, and comparisons of regulatory dynamics in major international markets. This provides a reference basis for compliant development and market access of products.

6. Representative Enterprises Presentation

The Blue Book will analyze the capital market performance of global and Chinese medical aesthetics injectables fields, including corporate financing, product licensing transactions, and industry integration events. In addition, the Blue Book will include a special section on enterprises to provide in-depth introductions to representative domestic and foreign enterprises, covering technical routes, product pipelines, commercial progress, and strategic layouts. Differentiated positions and core competitiveness will be presented in the industry panorama.

Frost & Sullivan invites outstanding enterprises in the field of medical aesthetics injectables to participate in the Blue Book. Together with multiple parties in the industrial chain, we will jointly participate in research and release processes, forming a rational expression and consensus accumulation regarding industry development under a professional analysis framework, and working together to promote the standardization and sustainable development of the Chinese medical aesthetics injectables industry.

Release Highlights

1. Global Release of Blue Book to Enhance Industry Visibility through Technical Strength

As a systematic research achievement in the field of medical aesthetics injectables, the Blue Book will be widely released through Frost & Sullivan’s official website, global media matrix, and life science vertical channels. The report will deeply present the core advantages of participating enterprises, focusing on the innovation of technical platforms, depth of product pipeline layout, key data, regulatory milestones, and large-scale production capabilities. By presenting differences, it helps the market establish a clear understanding of enterprise technical strength and industrialization capabilities, enhancing industry influence and brand credibility, and providing an authoritative platform for enterprises to express themselves and be displayed collectively.

The English version will also be published by globally renowned news agencies (such as The Associated Press), mainstream financial media (such as Yahoo Finance), North American financial media and websites (such as Business Insider, Dow Jones Market Watch, Benzinga, Wall Street Insider), and regional media channels around the world, further expanding the brand visibility of enterprises in the international market and helping Chinese medical aesthetics injectables enterprises promote global brand building and technical cooperation.

2. Connecting the Industrial Ecosystem and Expanding Cooperation Network

The Blue Book will establish a communication platform connecting multiple entities in the medical aesthetics injectables industry chain, promoting deep interaction and resource matching between enterprises with different positions. Raw material enterprises, product enterprises, medical aesthetic institutions, etc. can present their businesses differently, facilitating complementary integration through precise matching, enhancing mutual understanding with investment institutions and industry partners, and creating more possibilities for technical collaboration, resource integration, and business expansion.

3. Strengthening Professional Positioning and Creating Brand Recognition

With the systematic analysis of medical aesthetics injectables technology, commercial conversion paths, and regulatory science by the Blue Book, the professional accumulation of participating enterprises will be objectively presented. Through the deep presentation of research content, the recognition and influence of enterprises in technical platforms, product progress, or production capacity will be enhanced, strengthening differentiated market positioning.

4. Connecting with Diversified Capital and Seizing Strategic Opportunities

With Frost & Sullivan’s network of investment institutions and industry partners in the life science field, the release of the Blue Book effectively enhances the industry visibility of medical aesthetics injectables enterprises. It precisely connects with various types of capital: enterprises in the early research and development stage can attract venture capital funds focused on breakthrough in underlying materials with the innovation of their technical platforms; enterprises in the clinical or registration stage can connect with medical professional capital and large enterprise BD departments focused on product pipeline value and approval expectations; enterprises that have obtained certifications and started commercialization can attract strategic investors and industry acquirers with their product portfolio and market share. The Blue Book aims to build an efficient communication bridge between enterprises and diversified capital, helping them gain an advantage in financing, technology licensing, mergers and acquisitions, and strategic cooperation.

5. Deepening Long-Term Cooperation and Creating Industry Value Together

Based on the deep communication established through the Blue Book, Frost & Sullivan can explore multiple collaborative directions with participating enterprises, including brand promotion, investment and financing consulting, growth strategy, etc. Both parties are expected to establish a long-term partnership based on this cooperation, jointly addressing industry changes and working together to promote high-quality development of the medical aesthetics injectables industry.